• 1. Structures and biological activities of cycloheptamycins A and B
  Zhengyi Qian,Janine Antosch,Jutta Wiese,Johannes F. Imhoff,Hans-Peter Fiedler,Alexander P?thig,Tobias A. M. Gulder Org. Biomol. Chem. 2019 17 6595
• 2. Metabolic profiling reveals the heterogeneity of vascular endothelial function phenotypes in individuals at extreme cardiovascular risk
  Baoyu Mao,Yanshan Yi,Qiuyan Mo,Chunxiu Yang,Qiuan Zhong RSC Adv. 2019 9 30033
• 3. Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide C
  Luigi Margarucci,Maria Chiara Monti,Andrea Mencarelli,Chiara Cassiano,Stefano Fiorucci,Raffaele Riccio,Angela Zampella,Agostino Casapullo Mol. BioSyst. 2012 8 1412

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Introduction to (2R,3R)-2-Amino-3-methyloxybutanoic acid (CAS No. 104195-79-1)

CAS No. 104195-79-1 refers to a specific enantiomer of (2R,3R)-2-Amino-3-methyloxybutanoic acid, a compound of significant interest in the field of pharmaceutical chemistry and biochemistry. This molecule, characterized by its unique stereochemistry, has garnered attention due to its potential applications in drug development and metabolic studies. The precise stereochemical configuration at the 2R and 3R positions imparts distinct chemical and biological properties, making it a valuable scaffold for synthetic chemists and medicinal researchers.

The (2R,3R)-2-Amino-3-methyloxybutanoic acid structure is an example of a chiral amino acid derivative, which plays a crucial role in the synthesis of enantiomerically pure pharmaceuticals. The presence of the methoxy group at the third carbon and the amino group at the second carbon contributes to its reactivity and solubility characteristics. These features are particularly important in the design of enzyme inhibitors and chiral catalysts, where specific interactions with biological targets are essential for efficacy.

In recent years, there has been growing interest in the development of novel amino acid-based therapeutics due to their versatility and biocompatibility. The (2R,3R)-2-Amino-3-methyloxybutanoic acid derivative has been explored in several preclinical studies as a potential building block for more complex molecules. Its ability to participate in peptide coupling reactions and its stability under various conditions make it a promising candidate for further investigation.

One of the most compelling aspects of this compound is its potential role in modulating biological pathways associated with neurological disorders. Research has suggested that enantiomerically pure amino acids can exhibit differential effects on neural receptors and enzymes compared to their racemic counterparts. The (2R,3R)-configuration of this molecule may offer unique pharmacological properties that could be exploited in the treatment of conditions such as Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

Moreover, the methoxy group in (2R,3R)-2-Amino-3-methyloxybutanoic acid provides a site for further functionalization, allowing chemists to tailor the molecule for specific biological activities. This flexibility has led to its incorporation into various drug discovery programs aimed at identifying novel therapeutic agents. The compound's ability to serve as a precursor for more complex structures underscores its importance in synthetic organic chemistry.

Recent advances in computational chemistry have also highlighted the significance of stereochemistry in drug design. Molecular modeling studies have demonstrated that the (2R,3R)-configuration can enhance binding affinity to certain biological targets by optimizing interactions with key residues in protein binding pockets. These insights have guided efforts to develop more effective and selective drugs based on chiral amino acid derivatives.

The synthesis of (2R,3R)-2-Amino-3-methyloxybutanoic acid presents both challenges and opportunities for synthetic chemists. Traditional methods often rely on enzymatic resolutions or chiral auxiliaries to achieve high enantiomeric purity. However, recent innovations in asymmetric synthesis have provided more efficient routes to this compound, reducing costs and improving yields. These advancements are crucial for scaling up production for industrial applications.

In addition to its pharmaceutical applications, (2R,3R)-2-Amino-3-methyloxybutanoic acid has been investigated for its role in metabolic studies. Its structural similarity to naturally occurring amino acids makes it a useful tool for studying enzyme mechanisms and metabolic pathways. By incorporating this compound into experimental systems, researchers can gain insights into how enzymes recognize and process substrates, which is essential for understanding disease mechanisms and developing targeted therapies.

The future prospects for (2R,3R)-2-Amino-3-methyloxybutanoic acid are promising, with ongoing research exploring its potential in various therapeutic areas. As our understanding of stereochemistry continues to evolve, so too will the applications of this compound. Whether used as a building block for new drugs or as a tool for biochemical research, CAS No. 104195-79-1 represents an important contribution to modern chemistry and medicine.

• 4144-02-9(O-Methyl-L-threonine)
• 201353-89-1(H-Allo-thr(tbu)-OH)
• 537697-28-2(O-Methyl-d-threonine)
• 104195-80-4((2S,3S)-2-Amino-3-methoxybutanoicacid)
• 4378-13-6(H-Thr(tBu)-OH)
• 4385-90-4(O-methyl threonine)
• 131234-99-6((2S,3S)-2-Amino-3-ethoxybutanoic acid)
• 205503-95-3(L-Allothreonine,O-ethyl-, hydrochloride (9CI))
• 201274-81-9(H-D-Thr(tbu)-OH)
• 2076-57-5(Threonine, O-methyl-)